Navigation Links
Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
Date:4/14/2008

NEW HAVEN, Conn. and LONDON, April 14 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, and the Laboratory of Molecular Biology of the Medical Research Council (MRC) today announced they have renewed their research collaboration agreement in the area of ribosome and antibiotic structure and function for an additional year. Under the terms of the Agreement, Rib-X and the MRC will continue to jointly explore the high resolution crystal structure of the 70S ribosome.

"Using information discovered about the ribosome during our first year of work with the MRC, Rib-X has been able to advance the iterative intelligent discovery engine that the Company developed to design novel antibiotic scaffolds which circumvent the mechanisms employed by resistant bacteria," said Erin Duffy, Ph.D, Rib-X's Vice President of Structure-Based Drug Design. "This is a natural extension of our relationship with MRC, which will build upon Dr. Venki Ramakrishnan's discovery of the structure of the full 70S ribosome and, in turn, increase our understanding, on an atomic level, of the binding properties of antibiotics to the 50S subunit of the ribosome."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combines state of the art, proprietary computation
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Voalte, the leader ... leader in purpose-built wireless communications, today announced that ... a 104-bed acute-care facility in Webster, ... Voalte One™ solution on Spectralink PIVOT™ purpose-built smartphones ... named Voalte a member of its AIMS Partner ...
(Date:7/28/2015)... 2015 ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ... its second quarter and year-to-date 2015 financial results on ... U.S. financial markets. The earnings press release will be ... website, www.anipharmaceuticals.com . Arthur S. ... Charlotte C. Arnold , Vice President and Chief Financial ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Pharmaceutical Industry in China to 2020: ... Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, ... offering. This report tackles not ... China but also home grown companies ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2
... Feb. 16, 2012 OPKO Health, Inc. and ChromaDex ... a strategic alliance pursuant to which ChromaDex has licensed ... health care technologies for distribution and business development throughout ... commercialized are BluScience™ ( www.bluscience.com ), ChromaDex,s ...
... Food and Drug Administration (FDA) has recently issued alerts ... including , hair regrowth products that may ... over-the-counter medications that may contain the wrong tablets in ... cosmetics that contain an anesthetic drug ingredient and harmful ...
Cached Medicine Technology:OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... and Found, a breakthrough technological invention. It is a wearable personal tracking ... electronic industry reached a record high of $211.3 billion in 2014," says Scott ...
(Date:7/28/2015)... NJ (PRWEB) , ... July 28, 2015 , ... Morristown ... in New Jersey, and one of the first five hospitals in the nation, to ... in three patients on July 23, and all are in good condition. , The ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont ... visit to Ethiopia to learn more about the impact of U.S. collaborations with ... initiative focuses on accelerating agricultural development as an engine of broad-based economic growth ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Women in ... Washington, D.C. technology community for over 20 years, has selected Lisa Dezzutti, CEO and ... upcoming year. , “I am excited to serve this organization that empowers women to ...
(Date:7/28/2015)... ... July 28, 2015 , ... OrthAlign, Inc., a ... ORTHALIGN PLUS® system, a palm-sized, single-use navigation device for Total Hip Arthroplasty (cup ... with practicality in a revolutionary way for Total Knee Arthroplasty surgeries and is ...
Breaking Medicine News(10 mins):Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3
... Behen HealthDay Reporter , WEDNESDAY, Sept. 22 ... arthritis (RA) may benefit patients with this chronic autoimmune ... therapy, researchers say. The oral medication, known as ... of drugs known as spleen tyrosine kinase (Syk) inhibitors, ...
... The American Society for Radiation Oncology (ASTRO) is pleased ... Recipients will receive their honors during ASTRO,s 52nd Annual ... 2010. ,"It is my pleasure to congratulate each ... this year," Anthony L. Zietman, M.D., ASTRO president and ...
... international study of patients with a devastating type of dementia ... evidence that career choice may influence where the disease takes ... led by Baycrest,s Rotman Research Institute in collaboration with the ... Francisco and several U.S. and European clinical sites. It appears ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay News) -- ... 3-D movies, everyone seems to be oohing and ahhing over ... Well, almost everyone. "There will be at least one ... about? I didn,t see anything flying out at me., Or ...
... finds that college women with roommates who weigh more ... than women with slimmer roommates: half a pound versus ... freshman weight gain of 2.5-to-6 pounds---much less than the ... there are some good explanations for why it may ...
... PROVIDENCE, RI Damian Dupuy, MD, of Rhode Island ... from the American College of Radiology Imaging Network (ACRIN). ... on the use of radiofrequency ablation (RFA) to reduce ... the bone). The award recognizes a scientific paper published ...
Cached Medicine News:Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 2Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 3Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 4Health News:ASTRO announces 2010 Annual Meeting awards 2Health News:ASTRO announces 2010 Annual Meeting awards 3Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 2Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 3Health News:Vision Problems Can Rob Movie-Goers of 3-D 2Health News:Vision Problems Can Rob Movie-Goers of 3-D 3Health News:Freshman weight gain: Women with heavy roommates gain less 2Health News:Rhode Island Hospital physician receives national award for research 2
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
For quantitative determination of amylase in human serum....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Medicine Products: